Hemotoxicity Assay
Hematopoietic Stem Cells (HSCs) are the responsible to replenish mature blood cells after hematopoietic stresses. One of the most common dose limiting adverse effects in cancer treatment is myelosuppression, which describes adverse effects on the blood forming system. Here, we provide an assay to measure depletion of different subsets of CD34+ progenitors in Normal Bone Marrow (NBM) or other hematological diseases to potentially screen drug candidates and combinations for hematotoxicity, as well as personalize therapy to the individual sensitive patient at risk.
Tubeandbracket
  • NBM
  • AML
  • MM
Native Blook Cell Populations
  • Red Blood Cells
  • Platelets
  • Hematopoietic Precursor Cells
  • Others

Directed Toxicity against

Tarjet Arrow
Cytotoxic Drug Therapy
Plate Cytotoxic Drug

Hematological
Sample

Native Cell
Population

Drug
Incubation

Cells Retrieval &
FCM Readout

Hemotoxicity Assay:
Native Environment

Hematoxicity Assay
Hematological
Sample
Tubeandbracket
  • NBM
  • AML
  • MM
Native Cell Population
Native Blook Cell Populations
  • Red Blood Cells
  • Platelets
  • Hematopoietic Precursor Cells
  • Others
Drug Incubation
Directed Toxicity against CD34+/CD38- Cells
Tarjet Arrow
Cytotoxic Drug Therapy
Cells Retrieval & FCM Readout
Plate Cytotoxic Drug
Hemotoxicity Assay:
Native Environment
Hematoxicity Assay